Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics (GRTX)
NASDAQ:GRTX
Galera Therapeutics (GRTX) Stock Price & Analysis
209 Followers
GRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $3.50
Previous Close$3.04
Volume315.98K
Average Volume (3M)690.32K
Market Cap
$130.44M
Enterprise Value$82.69M
Total Cash (Recent Filing)$47.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.4
Beta1.62
Next Earnings
Aug 14, 2023EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding42,906,833
10 Day Avg. Volume696,742
30 Day Avg. Volume690,323
Standard Deviation0.47
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$11.00Price Target Upside264.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Galera Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $1.12 and its highest was $3.50 in the past 12 months.
What is Galera Therapeutics’s market cap?
Currently, no data Available
When is Galera Therapeutics’s upcoming earnings report date?
Galera Therapeutics’s upcoming earnings report date is Aug 14, 2023 which is in 76 days.
How were Galera Therapeutics’s earnings last quarter?
Galera Therapeutics released its earnings results on May 11, 2023. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.382 by -$0.118.
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Undervalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate is -$0.4.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 42,906,834 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Galera Therapeutics reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.382. Following the earnings report the stock price went down -1.893%.
Which hedge fund is a major shareholder of Galera Therapeutics?
Among the largest hedge funds holding Galera Therapeutics’s share is Blackstone Inc.. It holds Galera Therapeutics’s shares valued at 4M.
---
Galera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (264.24% Upside)
$11.00 (264.24% Upside)
Insider Transactions
Bought Shares
Worth $212.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Galera Therapeutics
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
---
Top 5 ETFs holding GRTX
iShares Core S&P Total U.S. Stock Market ETF
$35.76K
Up to five ETFs with an Outperform Smart Score that hold GRTX. The ETFs are listed according to market value of GRTX within the ETF
---
TCR2 Therapeutics
―
Cidara Therapeutics
―
SELLAS Life Sciences Group
―
Biora Therapeutics
―
Exagen
―
---